ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2341

Findings of Pulmonary Abnormalities on High Resolution Computed Tomography in a Cohort of Rheumatoid Arthritis Patients Without Known Lung Disease

Scott Matson1, Kevin Deane 2, Christopher Collora 1, Xi Zheng 1, Marie Fester 1, Joyce Lee 1 and M. Kristen Demoruelle 3, 1University of Colorado, Denver, 2University of Colorado Denver, Division of Rheumatology, Aurora, CO, USA, Aurora, CO, 3University of Colorado Denver, Division of Rheumatology, Aurora, CO, USA, Aurora

Meeting: 2019 ACR/ARP Annual Meeting

Keywords: anti-CCP antibodies and pulmonary fibrosis, interstitial lung disease, Pulmonary Involvement, Rheumatoid arthritis (RA)

  • Tweet
  • Email
  • Print
Session Information

Date: Tuesday, November 12, 2019

Title: RA – Diagnosis, Manifestations, & Outcomes Poster III: Comorbidities

Session Type: Poster Session (Tuesday)

Session Time: 9:00AM-11:00AM

Background/Purpose: Pulmonary manifestations of rheumatoid arthritis (RA) lead to significant morbidity and mortality. Lung manifestations in RA are myriad, however little is known about how to predict those patients at highest risk for development of clinically significant disease.

Methods: Methods: In this study we performed a screen for lung disease by high resolution computed tomography (HRCT) scan in a population of patients with RA without known interstitial lung disease. We also collected baseline demographics, clinical information and blood was tested for  RA associated antibodies including anti-CCP3 (IgG), CCP3.1 (IgG/IgA), and RF. Chest imaging was reviewed and interpreted by two radiologists with expertise in thoracic radiology who independently reviewed all HRCT scans using a scoring algorithm supplied by the research investigators. For those interpretations which were discriminant between readers, the radiologists discussed the case and came to consensus. We compared demographics (gender, age, duration of RA) and antibody profiles between RA patients with abnormal imaging on HRCT and those who did not have pulmonary disease.

Results: Results: We screened 55 patients from the rheumatology clinic at the University of Colorado, who denied having any lung disease, with HRCT. We found that 31% (n=17) of the patients had findings of pulmonary fibrosis (as defined by abnormal reticulations, evidence of traction bronchiectasis or honeycombing). These 17 patients were determined to have fibrosis in “possible” or “probable” usual interstitial pneumonia (UIP) pattern. We found that those patients with pulmonary fibrosis were older (65.3 vs 54.9 years, p=.007). There was no statistically significant difference in gender, smoking status, duration of RA or antibody profile between those with and without fibrosis. Of the 55 patients scanned, we also found that 62% (n=34) had airways disease as determined by consensus findings of air trapping and bronchial wall thickening without findings of emphysema. In this small cohort, there was no association between presence of airways disease and age, smoking status, duration of RA or antibody positivity.

Conclusion: In this at-risk population for lung disease, we found 31% of RA patients without known lung disease to have findings of pulmonary fibrosis and 62% to have HRCT findings of airways disease. Prospective study of an at risk population for development of lung disease may help inform screening methods.


Disclosure: S. Matson, None; K. Deane, Bristol-Myers Squibb, 5, Inova, 9, Janssen, 2, 5, Janssen R&D, 2, Microdrop, 5, Pfizer, 2; C. Collora, None; X. Zheng, None; M. Fester, None; J. Lee, None; M. Demoruelle, Pfizer, 2.

To cite this abstract in AMA style:

Matson S, Deane K, Collora C, Zheng X, Fester M, Lee J, Demoruelle M. Findings of Pulmonary Abnormalities on High Resolution Computed Tomography in a Cohort of Rheumatoid Arthritis Patients Without Known Lung Disease [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10). https://acrabstracts.org/abstract/findings-of-pulmonary-abnormalities-on-high-resolution-computed-tomography-in-a-cohort-of-rheumatoid-arthritis-patients-without-known-lung-disease/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2019 ACR/ARP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/findings-of-pulmonary-abnormalities-on-high-resolution-computed-tomography-in-a-cohort-of-rheumatoid-arthritis-patients-without-known-lung-disease/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology